Shenzhen Infinova Limited(002528) : announcement of abnormal fluctuations in stock trading

Securities code: 002528 securities abbreviation: Shenzhen Infinova Limited(002528) Announcement No.: 2022-017 Shenzhen Infinova Limited(002528)

Announcement of abnormal fluctuations in stock trading

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.

1、 Introduction to abnormal fluctuations in stock trading

Shenzhen Infinova Limited(002528) (hereinafter referred to as the company) (Securities abbreviation: Shenzhen Infinova Limited(002528) ; securities code: 002528) within three consecutive trading days (January 27, 2022, January 28, 2022 and February 7, 2022), the deviation of the closing price has exceeded 20% in total. According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, It belongs to abnormal fluctuation of stock trading.

2、 Description of the company’s concern and verification

In view of the abnormal fluctuation of the company’s stock trading, the company has checked the relevant matters, and now the relevant information is explained as follows:

1. There is no need to correct or supplement the information disclosed by the company in the early stage;

2. The company has not found any unpublished material information that may or has had a great impact on the stock trading price of the company reported by the public media recently;

3. The company’s recent operation is normal, and the internal and external business environment has not changed significantly;

4. The company, the controlling shareholder and the actual controller have no major matters that should be disclosed but not disclosed about the company, and there are no major matters in the planning stage;

5. The controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of stock trading; 6. The company did not find any other matters that should be disclosed in the process of attention and verification.

3、 Whether there is a description of the information that should be disclosed but not disclosed

The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the Listing Rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares and their derivatives that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; The information disclosed by the company in the early stage does not need to be corrected or supplemented.

4、 Risk tips

1. Through self-examination, the company does not violate the fair disclosure of information.

2. The company disclosed the performance forecast for 2021 (Announcement No.: 2022-014) on January 27, 2022. It is estimated that the net profit attributable to the shareholders of the listed company in 2021 will be a loss of 90 million yuan – 135 million yuan (the estimated impairment of goodwill assets is 500 million yuan – 714.71 million yuan). As of the disclosure date of this announcement, the above performance is not expected to be corrected. The specific financial data of the company in 2021 shall be subject to the annual report of the company in 2021.

3. The company solemnly reminds investors: securities times, Securities Daily, China Securities News, Shanghai Securities News and cninfo (www.cn. Info. Com. CN.) For the information disclosure media selected by the company, all information of the company shall be subject to the information published in the above media. Please invest rationally and pay attention to risks.

It is hereby announced.

Shenzhen Infinova Limited(002528) board of directors

February 8, 2022

- Advertisment -